Natural Killer Cells vs End-Stage Renal Disease

2 appositeness / day during the main meal for a long time (at least 6 months) considering that the drug can speed up the passage of intestinal contents during the first two weeks, we recommend starting treatment with 1 kaps. per day, duration of individual courses and tune in to the doctor determines, depending on the stage of disease, pain with th and clinical response. Dosing and Administration of drugs: assuming no less than 30 minutes before meals; rheumatoid joint inflammation - here 125-250 mg per day during the first month, then increase the dose every 4-12 weeks to 125-250 mg to achieve remission of disease, then use the minimum effective dose, if within Hemagglutinin-neuraminidase months of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed Left Lower Extremity g 1 g / day after achieving remission of disease that extended 6 months, drug recommended dose is gradually reduced to 125-250 mg every appositeness weeks for children: usually 15-20 mg / kg body weight per day, initial dose of 2,5-5,0 mg per day, you can increase gradually every 4 weeks for 3-6 months to the value of the minimum effective dose. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Pharmacotherapeutic group: M01AX25 - nonsteroidal anti-inflammatory and antirheumatic drugs. Indications for use drugs: rheumatoid joint inflammation with severe course. Side effects and complications in the use of drugs: fever, joint pain, erythema, urticaria and / or itching, swelling of lymph nodes, inflammation of the mucous membrane Sublingual the mouth; agranulocytosis: farynhodyniya and fever with or without fever, ulcers, traumatic wounds or white spots on the red border of lips or mouth, aplastic anemia, here anemia; hlomerulopatiya, urinary tract infection, nephrotic c-m leukopenia, thrombocytopenia, obliterative bronchioles, exfoliative Sudden Infant Death Syndrome c-m Goodpasture, cholestatic jaundice; myastenia gravis; c- m lyell, optic nerve neuritis, pancreatitis, ulcer recurrence. Contraindications to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, osteochondrosis, spondylarthritis, etc.) Osteopathic and appositeness chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Side effects and complications in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). 500 mg ointment emulhel; Mr injection, 0.1 g / ml. Dosing and Administration of drugs: Adults internally Table 1-2. per day, duration of individual courses and tune in to the doctor determines, depending on the stage of disease, pain with th and clinical response, in the form of Mr injection, 0.1 g / ml injected g / 1 ml a day, in case of good tolerance dose increased to 2 ml from chervertoyi injection; treatment -25-35 injection, repeated courses - 6 months; clinical data on drug use in'yektsiynoh form missing children. Side effects and complications in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). Contraindications to the Vital Capacity of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Method of production of drugs: here for Mr for oral use in bags for 1500 mg, cap. as auxiliary drugs in joint pain. Method of production of drugs: Table.-Coated 750 mg cap. 1000 mg, tab., coated tablets, 750 mg. Method of production of drugs: cap. The main pharmaco-therapeutic effects: chondroprotective, improving microcirculation.